
Hunenberg, Switzerland—The Australian Therapeutics Goods Administration has approved Alcon Inc.'s anecortave acetate suspension 15 mg (RETAANE) for the treatment of subfoveal choroidal neovascularization caused by exudative age-related macular degeneration (wet AMD) where there is a classic component.
